Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083282 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL10476744 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL14503133 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL4083394 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL10476678 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL3742301 | 1.00 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL12276963 | 0.87 | GABRR1 (0.50) | GABRR1SLC1A2LMNACYP2C19PMP22 | |
| SCHEMBL28265022 | 0.84 | — | — | |
| SCHEMBL28934977 | 0.83 | — | — | |
| SCHEMBL6580400 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230118-A1 | TWO-STAGE PROCESS FOR PRODUCING TETRAALKYL 1,2,3,4 BUTANETETRACARBOXYLATES | EVONIK OXENO GMBH & CO. KG (DE) | 2025-07-17 | — | — | US | disclosed |
| US-11149202-B1 | Tetracarboxylic acid combinations for corrosion inhibition | ECOLAB USA INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149202-B1 | Tetracarboxylic acid combinations for corrosion inhibition | ECOLAB USA INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| CN-101166709-B | Process for preparing tetracarboxylic acids | BASF AG | 2011-03-30 | — | — | CN | disclosed |
| US-7834211-B2 | Method for producing tetracarboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2010-11-16 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090124827-A1 | Method For Producing Tetracarboxylic Acids | BASF AKTIENGESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-1877358-B1 | METHOD FOR PRODUCING TETRACARBOXYLIC ACIDS | BASF SE (DE) | 2008-12-17 | — | — | EP | disclosed |
| CN-101166709-A | Process for preparing tetracarboxylic acids | BASF AG (DE) | 2008-04-23 | — | — | CN | disclosed |
| EP-1877358-A1 | METHOD FOR PRODUCING TETRACARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| WO-2006117326-A1 | METHOD FOR PRODUCING TETRACARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-09 | — | — | WO | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-5157152-A | Process for the oxidation of a tetrahydrophthalic acid | ORTEC, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5047582-A | Process for the oxidation of a tetrahydrophthalic acid | ORTEC, INC. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230118-A1 | TWO-STAGE PROCESS FOR PRODUCING TETRAALKYL 1,2,3,4 BUTANETETRACARBOXYLATES | ADH1A, ADH1C, TBCA | GABRR1 1301/4885SLC1A2 2209/4885LMNA 1610/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | GABRR1 4000/4885SLC1A2 2591/4885LMNA 814/4885 |
| US-11149202-B1 | Tetracarboxylic acid combinations for corrosion inhibition | CA1, TMCO1, CTRC | GABRR1 1450/4885SLC1A2 2279/4885LMNA 3560/4885 |
| US-20090124827-A1 | Method For Producing Tetracarboxylic Acids | CBR1, AOC2, NOS2 | GABRR1 864/4885SLC1A2 2170/4885LMNA 2083/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | GABRR1 4000/4885SLC1A2 2591/4885LMNA 814/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | GABRR1 3036/4885SLC1A2 2255/4885LMNA 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.